Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and Food Effect of HSK55879 in Healthy Subjects
NCT07521345Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing HSK55879 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 15 days. Started Mar 2026; status: recruiting.
02
Drugs
HSK55879
Beyond the preview
Go deeper on NCT07521345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521345.